Novartis' HSR waiting period for acquiring Regulus Therapeutics Inc. has expired

From GlobeNewswire: 2025-06-23 01:00:00

Novartis has announced the expiration of the waiting period under the HSR Act for its tender offer to acquire Regulus Therapeutics Inc. The offer includes $7.00 in cash per share and one contingent value right (CVR) per share, representing the right to receive an additional $7.00 in cash upon a regulatory milestone achievement. This satisfies a condition for the merger, pending a majority of shares tendered. The offer will expire on June 24, 2025, unless extended. Investors and security holders are advised to review the tender offer materials and solicitation/recommendation statement before making any decisions. Novartis is an innovative medicines company focused on improving and extending lives.



Read more at GlobeNewswire: Novartis announces expiration of HSR waiting period of